Trial Profile

Phase IIb trial of an oral formulation of testosterone undecanoate in adult males with primary or secondary hypogonadism.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 May 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Testosterone undecanoate (Primary)
Indications Hypogonadism
Focus Therapeutic Use
Sponsors SOV Therapeutics

Most Recent Events

08 Mar 2015 Results presented at The 97th Annual Meeting of the Endocrine Society.
24 Dec 2014 New trial record
16 Dec 2014 Primary endpoint has been met (testosterone replacement), according to a SOV Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com